Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7811979 | 0.81 | CA1 (0.32) | CA1CA2CA4KMT2A | |
| Hydrochloric Acid SCHEMBL6351637 | 0.72 | — | — | |
| SCHEMBL557849 | 0.67 | — | — | |
| Hydrochloric Acid SCHEMBL13737719 | 0.65 | CHRNA7 (0.34) | LMNAMAPTL3MBTL1 | |
| SCHEMBL6735640 | 0.64 | LMNA (0.33) | LMNAMAPTL3MBTL1CA1CA2 | |
| SCHEMBL416250 | 0.64 | HTR3B (0.30) | — | |
| SCHEMBL6995312 | 0.62 | LMNA (0.40) | LMNAMAPTL3MBTL1CA1CA2 | |
| SCHEMBL5765214 | 0.62 | LMNA (0.40) | LMNAMAPTL3MBTL1CA1CA2 | |
| Hydrochloric Acid SCHEMBL6348949 | 0.62 | — | — | |
| SCHEMBL3401334 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1404682-B1 | METHOD OF INHIBITING PTP 1B AND/OR T-CELL PTP AND/OR OTHER PTPASES WITH AN ASP RESIDUE AT POSITION 48 | NOVO NORDISK AS (DK) | 2005-09-14 | — | — | EP | disclosed |
| EP-1404682-A1 | METHOD OF INHIBITING PTP 1B AND/OR T-CELL PTP AND/OR OTHER PTPASES WITH AN ASP RESIDUE AT POSITION 48 | Novo Nordisk A/S (DK) | 2004-04-07 | — | — | EP | disclosed |
| US-20030064979-A1 | Method of inhibiting PTP 1B and /or T-cell PTP and/or other PTPases with an Asp residue at position 48 | NOVO NORDISK A/S (DK) | 2003-04-03 | — | — | US | disclosed |
| WO-2003002569-A1 | METHOD OF INHIBITING PTP 1B AND/OR T-CELL PTP AND/OR OTHER PTPASES WITH AN ASP RESIDUE AT POSITION 48 | NOVO NORDISK A/S (DK) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064979-A1 | Method of inhibiting PTP 1B and /or T-cell PTP and/or other PTPases with an Asp residue at position 48 | PTPRO, PTPRF, PTPA | LMNA 4870/4885MAPT 2025/4885L3MBTL1 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.